Interventional Pulmonary Market Set to Mirror Growth of Interventional Cardiology Market as New Technologies Drive U.S. Pulmonary Sales to $3.8 Billion in 2011

Pulmonary disease remains one of the major untapped medical device opportunities in the U.S. Not only are most of the diagnostic technologies employed underutilized, but treatment options have been limited. Sleep apnea was the first pulmonary disease to demonstrate the massive potential of this market, and product sales are far from peaking. Now, emerging minimally invasive and interventional therapies for asthma and COPD are preparing to drive similar, significant growth as they improve outcomes for drug-refractory patients and stimulate diagnostic testing. Moreover, new technologies are expected to enable screening and, hence, earlier diagnosis and characterization of a full range of...

Want to see the full article?

• Purchase this article for only $3.00